This is a working overview of actin binding, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-01-04. Anything still debated is marked as such rather than presented as settled.
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | Approximately 4963 Da for full-length thymosin beta-4 | Value applies to the parent protein; fragment products may differ |
| Appearance | White to off-white lyophilized powder | Typical form of supplied synthetic peptide |
| Solubility | Freely soluble in water | Polar peptide; dissolves readily in aqueous buffer |
| Storage of dry powder | −20 °C, desiccated, protected from light | Standard laboratory practice for peptides |
| Typical detection method | Liquid chromatography–tandem mass spectrometry | Used in purity testing and anti-doping analysis |
Peptide bonds are susceptible to hydrolysis under extreme pH and to enzymatic cleavage if proteases are present. Heat, oxidising agents, and prolonged exposure to light also contribute to loss of material. Aggregation can occur at high concentrations or in certain buffer systems, and it may not be visible to the eye. Storage at -20 C or below is typical for both powder and aliquoted solutions, and desiccation of the powder is preferred.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography together with mass spectrometry. The chromatogram provides a purity estimate as a percentage of total peak area, while the mass spectrum confirms that the observed mass matches the expected value. Amino acid analysis or tandem mass spectrometry sequencing can provide additional confirmation. Reported purity figures depend on the column, gradient, and detection wavelength, so values from different laboratories are not directly comparable without method details.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
Once a drug's bioavailability has been established it is possible to calculate the changes that need to be made to its dosage in order to reach the required blood plasma levels. Bioavailability is, therefore, a mathematical factor for each individual drug that influences the administered dose. It is possible to calculate the amount of a drug in the blood plasma that has a real potential to bring about its effect using the formula:
This was from the notion that depression was primarily due to norepinephrine deficits, partly based on the fact that drugs that relieve depression increase brain norepinephrine levels. To date, a great number of potent and selective and mixed norepinephrine reuptake inhibitors (NRIs) have been marketed as antidepressants. The first commercially available selective norepinephrine reuptake inhibitor (sNRI) was reboxetine (Edronax) and was developed as a first-line therapy for major depressive disorder. The selectivity of reboxetine for the norepinephrine transporter (NET) results in benign side effect profile because the drug is well tolerated. In the laboratories of Chemistry of Farmitalia Carlo Erba (Milan, Italy), reboxetine was synthesized according to the general method described by Melloni et al. In 1993 Kabi Pharmacia, Swedish based pharmaceutical giant, bought Farmitalian and in 2003 Pfizer bought Pharmacia. Atomoxetine (Strattera) is another potent and selective NRI which is also effective and well tolerated treatment for adults with ADHD. This drug was the first ADHD treatment to be specially approved for adult use. Studies showed that atomoxetine is a nonstimulant and carries negligible risk of abuse. This discovery was groundbreaking as a beneficial new treatment option for adults with ADHD, specially those patients at risk of substance abuse.
==== Elderly ==== Although obesity is reported in the elderly, the numbers are still significantly lower than the levels seen in the young adult population. It is speculated that socioeconomic factors may play a role in this age group when it comes to developing obesity. Obesity in the elderly increases healthcare costs. Nursing homes are not equipped with the proper equipment needed to maintain a safe environment for the obese residents. If a heavy bedridden patient is not turned, the chances of a bed sore increases. If the sore is untreated, the patient will need to be hospitalized and have a wound vac placed.
=== Common fundamentals === In any form of chromatography, the rate at which the solute moves down the column is a direct reflection of the percentage of time the solute spends in the mobile phase. To achieve separation in either elution or displacement chromatography, there must be appreciable differences in the affinity of the respective solutes for the stationary phase. Both methods rely on movement down the column to amplify the effect of small differences in distribution between the two phases. Distribution between the mobile and stationary phases is described by the binding isotherm, a plot of solute bound to (or partitioned into) the stationary phase as a function of concentration in the mobile phase. The isotherm is often linear, or approximately so, at low concentrations, but commonly curves (concave-downward) at higher concentrations as the stationary phase becomes saturated.
== Structure == Transpeptidases are members of the penicilloyl-serine transferase superfamily, which has a signature SxxK conserved motif. With "x" denoting a variable amino acid residue, the transpeptidases of this superfamily show a trend in the form of three motifs: SxxK, SxN (or analogue), and KTG (or analogue). These motifs occur at equivalent places, and are roughly equally spaced, along the polypeptide chain. The folded protein brings these motifs close to each other at the catalytic center between an all-α domain and an α/β domain. The structure of the streptomyces K15 DD-transpeptidase has been studied, and consists of a single polypeptide chain organized into two domains. One domain contains mainly α-helices, and the second one is of α/β-type. The center of the catalytic cleft is occupied by the Ser35-Thr36-Thr37-Lys38 tetrad, which includes the nucleophilic Ser35 residue at the amino-terminal end of helix α2. One side of the cavity is defined by the Ser96-Gly97-Cys98 loop connecting helices α4 and α5. The Lys213-Thr214-Gly215 triad lies on strand β3 on the opposite side of the cavity. The backbone NH group of the essential Ser35 residue and that of Ser216 downstream from the motif Lys213-Thr214-Gly215 occupy positions that are compatible with the oxyanion hole function required for catalysis. The enzyme is classified as a DD-transpeptidase because the susceptible peptide bond of the carbonyl donor extends between two carbon atoms with the D-configuration.
Sources: en.wikipedia.org
=== Heart failure === In heart failure patients, angiotensin receptor blockers such as candesartan and valsartan may be a suitable option for those who do not tolerate angiotensin-converting enzyme inhibitor medicines. Randomised control trials have shown candesartan reduces heart failure hospitalisations and cardiovascular deaths for patients who have heart failure with reduced left ventricular ejection fraction (LVEF ≤ 40%).
== See also == RO5166017 – TAAR1 partial or full agonist RO5203648 – TAAR1 partial agonist RO5256390 – TAAR1 partial or full agonist RO5263397 – TAAR1 partial agonist EPPTB – TAAR1 antagonist/inverse agonist
== Transplantation and gene therapy == Hematopoietic stem cells (HSC) are cells in the bone marrow that can develop into all types of blood cells, including red blood cells, white blood cells, and platelets. There are two possible ways to treat hemoglobinopathies by targeting HSCs. One is to transplant HSCs from a healthy donor into the patient's bone marrow; this was pioneered in 1981. More recently, it has become possible to use CRISPR gene editing technology to modify the patient's own HSCs in a way that increases production of functional beta-globin chains, leading to near normal levels of healthy hemoglobin. All stem cell treatments must involve myeloablation of the patients' bone marrow in order to remove HSCs containing the faulty gene. This requires high doses of chemotherapy agents with side effects such as sickness and tiredness. A long hospital stay is necessary after infusion of the replacement HSCs while the cells take up residence in the bone marrow and start to make red blood cells with the stable form of haemoglobin.
Wenger's arrival at Arsenal was greeted with perplexity by some of the club's players, supporters and the local media. Although he was touted as a future technical director of The Football Association (FA), he was relatively unknown in English football. Glenn Moore's report in The Independent, dated 24 September 1996, highlighted the mood: "It is a measure of the insularity of the English game that when Arsène Wenger's name emerged as Arsenal's favoured candidate for their vacant manager's job many supporters were asking: 'Arsène who?'" Unlike his predecessors, Wenger was given control over transfers, contracts and training sessions, and the Arsenal board chose not to meddle in team affairs. One of his first acts as manager was to assure the experienced players they had a future at the club, but he noted the squad was "a bit tight," and needed competition for places. Wenger adopted a hands-on approach to training sessions which energised the squad, and made steps to change the drinking culture that afflicted Arsenal. Although he initially allowed players to have a pint of beer, they were forbidden to drink on days off and in the players' lounge. He later banned his players from casually drinking together. Wenger also promoted pasta as the pre-match dish, encouraged boiled chicken instead of red meat and discouraged junk food. Players received optional vitamin injections and Creatine, which reduced fatigue and improved their stamina.
Sources: en.wikipedia.org
Not necessarily. TB-500 is a commercial label that suppliers apply to synthetic peptides described as thymosin beta-4 or a fragment of it. Published research most often studies the full-length protein, so statements about one do not automatically transfer to the other.
No. No major regulatory authority lists an approved product under this name, and no pharmacopoeial monograph exists for it. Material sold under the label is therefore supplied outside approved pharmaceutical channels, which affects the quality documentation available.
It falls within a prohibited class covering peptide hormones and growth factors, based on presumed effects on tissue repair and blood vessel formation. Anti-doping laboratories have published mass spectrometry methods for detecting thymosin beta-4 related peptides in urine samples.
No. TB-500 is a trade-style label used for a synthetic peptide described as a fragment of thymosin beta-4, while thymosin beta-4 is the full 43-residue protein. The two differ in size and are not interchangeable terms in analytical work.